Company Encyclopedia
View More
name
Atossa Therapeutics
ATOS.US
Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company’s lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs.
1.945 T
ATOS.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Strategic Advancements and Regulatory Progress Boost Atossa Therapeutics’ Outlook

    Emily Bodnar from H.C. Wainwright maintains a Buy rating for Atossa Therapeutics with a $7.00 price target. The positive outlook is due to strategic advancements in Atossa's clinical development for Z-endoxifen, particularly in breast cancer treatment. A Type C FDA meeting provided insights for expedited regulatory pathways, aiding multiple development tracks. Atossa's Phase 2 EVANGELINE trial design amendment aims to accelerate data readouts and conserve resources. These factors, along with Z-endoxifen's favorable safety profile, support the Buy rating.

    Tip Ranks·
    US
    ATOS
    +5.24%
    Tip Ranks·
    US
    ATOS
    +5.24%

    Atossa Completes FDA Meeting on Regulatory Strategies

    Atossa Therapeutics announced the completion of a Type C meeting with the FDA to discuss regulatory strategies for (Z)-endoxifen, aiming to expedite its development for breast cancer treatment. The FDA's feedback may accelerate Atossa's clinical and regulatory processes. Despite this progress, Atossa faces financial challenges, with analysts giving mixed ratings on its stock.

    Tip Ranks·
    US
    ATOS
    +5.24%
    Tip Ranks·
    US
    ATOS
    +5.24%

    Atossa Therapeutics and Insilico Medicine Identify (Z)-Endoxifen as Potential Glioblastoma Treatment in AI-Driven Study

    Atossa Therapeutics Inc., in collaboration with Insilico Medicine, has published a study identifying (Z)-endoxifen as a potential treatment for glioblastoma multiforme (GBM) using AI technology. The study, published in Nature Scientific Reports, highlights GBM as a promising candidate for further research. While no clinical trials have been announced, the findings suggest potential future therapeutic programs.

    Reuters·
    US
    ATOS
    +5.24%
    Reuters·
    US
    ATOS
    +5.24%

    Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific Presentation | ATOS Stock News

    Atossa Therapeutics highlights the potential of (Z)-Endoxifen in treating Duchenne Muscular Dystrophy (DMD) and Duchenne carrier-associated pathologies. A peer-reviewed article and upcoming scientific presentation support its multi-pathway efficacy. The therapy may offer consistent therapeutic exposures and complement existing treatments. Atossa plans to rigorously test (Z)-Endoxifen as an adjunct therapy in DMD and explore its use for symptomatic carriers. The company aims to engage regulators early to accelerate development for patients.

    StockTitan·
    US
    ATOS
    +5.24%
    StockTitan·
    US
    ATOS
    +5.24%

    Atossa Therapeutics: Strategic Advancements in Breast Cancer Treatment Drive Buy Rating

    Wall Street analyst Jason McCarthy from Maxim Group maintains a Buy rating on Atossa Therapeutics with a $4.00 price target, citing strategic advancements in breast cancer treatment. The company's low-dose endoxifen program and high-dose endoxifen initiative for metastatic ER+/HER2– breast cancer are key factors. A favorable FDA interaction could boost stock value. McCarthy's optimistic outlook is supported by Atossa's cash position, despite his average return of -14.4% and 33.20% success rate on stocks.

    Tip Ranks·
    US
    ATOS
    +5.24%
    Tip Ranks·
    US
    ATOS
    +5.24%
    © 2025 Longbridge｜Disclaimer